Jazz to Acquire GW Pharmaceuticals for $7.2B

 Jazz to Acquire GW Pharmaceuticals for $7.2B

Jazz to Acquire GW Pharmaceuticals for $7.2B

Shots:

  • Jazz to acquire GW Pharmaceuticals for $220/ GW ADS, out of which $200 in cash and $20 in Jazz ordinary shares, making a total deal value $7.2B with a 50% premium over a GW’s closing stock price on Feb 2, 2021. The transaction expected to close in Q2’21
  • The acquisition will expand Jazz’ neuroscience portfolio and expand its footprints with the addition of Epidiolex which is the first and only FDA-approved prescription cannabidiol medicine
  • Apart from Epidiolex, GW’s pipeline includes nabiximol for spasticity associated with MS and spinal cord injury as well as earlier-stage cannabinoid therapies for autism and schizophrenia

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Cannin

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post